The expression of proline-specific enzymes in the human lung

Annals of Translational Medicine

Volumn 5, Issue 6, 2017, Pages

  Vliegen, Gwendolyn ^a   Raju, Tom K ^a   Adriaensen, Dirk ^b   Lambeir, Anne Marie ^a   de Meester, Ingrid ^a  

^a UIA   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

(FAP); Dipeptidyl peptidase 4 (DPP4); Dipeptidyl peptidase 8 (DPP8); Dipeptidyl peptidase 9 (DPP9); Fibroblast activation protein; Lung; Prolyl oligopeptidase (PREP)

Indexed keywords

DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IX; DIPEPTIDYL PEPTIDASE VIII; MESSENGER RNA; PROLINE IMINOPEPTIDASE; PROLYL ENDOPEPTIDASE; SEPRASE; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; CELL SPECIFICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME SUBSTRATE COMPLEX; FIBROSING ALVEOLITIS; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG DISEASE; LUNG FIBROSIS; NONHUMAN; PATHOPHYSIOLOGY; PLEURA MESOTHELIOMA; PNEUMONIA; PROTEIN EXPRESSION; PROTEIN INTERACTION; REPERFUSION INJURY;

EID: 85016277577     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.21037/atm.2017.03.36     Document Type: Article

References (144)

1. WHO. The top 10 causes of death. 2014. Cited 2016 Oct 28. Available online: http://www. who. int/mediacentre/factsheets/fs310/en/
2. WHO. Asthma Fact Sheet N°307. 2013, Cited 2016 Oct 12. Available online: http://www. who. int/mediacentre/factsheets/fs307/en/
3. WHO. Cancer Fact Sheet N°297. 2015. Cited 2016 Oct 12. Available online: http://www. who. int/mediacentre/factsheets/fs297/en/
4. Bühling F, Groneberg D, Welte T. Proteases and their role in chronic inflammatory lung diseases. Curr Drug Targets 2006; 7: 751-9.
5. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-88.
6. Rawlings ND, Barrett AJ, Finn RD. Twenty years of the MEROPS database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 2016; 44: D343-D350.
7. Rawlings ND, Barrett AJ, Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 2012; 40: D343-50.
8. Aertgeerts K, Ye S, Tennant MG, et al. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci 2004; 13: 412-21.
9. Rasmussen HB, Branner S, Wiberg FC, et al. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003; 10: 19-25.
10. Aertgeerts K, Levin I, Shi L, et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem 2005; 280: 19441-4.
11. Fülöp V Böcskei Z, Polgár L. Prolyl Oligopeptidase: An Unusual B-Propeller Domain Regulates Proteolysis. Cell 1998; 94: 161-70.
12. Rummey C, Metz G. Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Proteins 2007; 66: 160-71.
13. Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-betanaphthylamide. Histochemie 1966; 7: 197-201.
14. Yoshimoto T, Fischl M, Orlowski RC, et al. Post-proline cleaving enzyme and post-proline dipeptidyl aminopeptidase. Comparison of two peptidases with high specificity for proline residues. J Biol Chem 1978; 253: 3708-16.
15. Tanaka T, Camerini D, Seed B, et al. Cloning and functional expression of the T cell activation antigen CD26. J Immunol 1992; 149: 481-6.
16. Hopsu-Havu VK, Jansén CT, Järvinen M. A human serum aminopeptidase capable of splitting juxtaterminal bonds involving proline. Basic characteristics, normal values and clinical variations. Clin Chim Acta 1970; 28: 25-36.
17. Wang Z, Grigo C, Steinbeck J, et al. Soluble DPP4 originates in part from bone marrow cells and not from the kidney. Peptides 2014; 57: 109-17.
18. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60: 1917-25.
19. Raschke S, Eckardt K, Bjørklund Holven K, et al. Identification and validation of novel contraction-regulated myokines released from primary human skeletal muscle cells. PLoS One 2013; 8: e62008.
20. Röhrborn D, Eckel J, Sell H. Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. FEBS Lett 2014; 588: 3870-7.
21. Darmoul D, Voisin T, Couvineau A, et al. Regional expression of epithelial dipeptidyl peptidase IV in the human intestines. Biochem Biophys Res Commun 1994; 203: 1224-9.
22. Kettmann U, Humbel B, Holzhausen HJ. Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney. Acta Histochem 1992; 92: 225-7.
23. The Human Protein Atlas. Tissue expression of DPP4 -Summary. Cited 2016 May 18. Available online: http://www. proteinatlas. org/ENSG00000197635-DPP4/tissue#gene_information
24. Matheeussen V, Baerts L, De Meyer G, et al. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem 2011; 392: 189-98.
25. Bengsch B, Seigel B, Flecken T, et al. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol 2012; 188: 5438-47.
26. Morimoto C, Torimoto Y, Levinson G, et al. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol 1989; 143: 3430-9.
27. Waumans Y, Baerts L, Kehoe K, et al. The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis. Front Immunol 2015; 6: 387.
28. Klemann C, Wagner L, Stephan M, et al. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. Clin Exp Immunol 2016; 185: 1-21.
29. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-35.
30. Mentlein R, Dahms P, Grandt D, et al. Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 1993; 49: 133-44.
31. Proost P. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001; 98: 3554-61.
32. Proost P. Amino-terminal Truncation of Chemokines by CD26/Dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor ofmonocyte chemotaxic and HIV-1-infection. J Biol Chem 1998; 273: 7222-7.
33. Crump MP, Gong JH, Loetscher P, et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 1997; 16: 6996-7007.
34. Lambeir AM, Durinx C, Scharpé S, et al. Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40: 209-94.
35. De Meester I, Vanham G, Kestens L, et al. Binding of adenosine deaminase to the lymphocyte surface via CD26. Eur J Immunol 1994; 24: 566-70.
36. Kameoka J, Tanaka T, Nojima Y, et al. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993; 261: 466-9.
37. Ohnuma K, Yamochi T, Uchiyama M, et al. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci U S A 2004; 101: 14186-91.
38. Ikushima H, Munakata Y, Ishii T, et al. Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor Ikushima H, Munakata Y, Ishii T, et al. Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor receptor contributes to T cell activation. Proc Natl Acad Sci U S A 2000; 97: 8439-44.
39. Ikushima H, Munakata Y, Iwata S, et al. Soluble CD26/ dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/ insulin-like growth factor II receptor. Cell Immunol 2002; 215: 106-10.
40. Girardi ACC, Fukuda LE, Rossoni LV, et al. Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol 2008; 294: F414-22.
41. Cheng H-C, Abdel-Ghany M, Pauli BU. A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. J Biol Chem 2003; 278: 24600-7.
42. Löster K, Zeilinger K, Schuppan D, et al. The cysteinerich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem Biophys Res Commun 1995; 217: 341-8.
43. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001; 54: 249-64.
44. Sato T, Yamochi T, Yamochi T, et al. CD26 Regulates p38 Mitogen-Activated Protein Kinase-Dependent Phosphorylation of Integrin B1, Adhesion to Extracellular Matrix, and Tumorigenicity of T-anaplastic large cell lymphoma Karpas 299. Cancer Res 2005; 65: 6950-6.
45. Abbott CA, Yu DM, Woollatt E, et al. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000; 267: 6140-50.
46. Olsen C, Wagtmann N. Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene 2002; 299: 185-93.
47. Justa-Schuch D, Möller U, Geiss-Friedlander R The amino terminus extension in the long dipeptidyl peptidase 9 isoform contains a nuclear localization signal targeting the active peptidase to the nucleus. Cell Mol Life Sci 2014; 71: 3611-26.
48. Gall MG, Chen Y, Vieira de Ribeiro AJ, et al. Targeted inactivation of dipeptidyl peptidase 9 enzymatic activity causes mouse neonate lethality. PLoS One 2013; 8: e78378.
49. Chen Y, Gall MG, Zhang H, et al. Dipeptidyl peptidase 9 enzymatic activity influences the expression of neonatal metabolic genes. Exp Cell Res 2016; 342: 72-82.
50. Bjelke JR, Christensen J, Nielsen PF, et al. Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochem J 2006; 396: 391-9.
51. Geiss-Friedlander R Parmentier N, Möller U, et al. The cytoplasmic peptidase DPP9 is rate-limiting for degradation of proline-containing peptides. J Biol Chem 2009; 284: 27211-9.
52. Han R Wang X, Bachovchin W, et al. Inhibition of dipeptidyl peptidase 8/9 impairs preadipocyte differentiation. Sci Rep 2015; 5: 12348.
53. Matheeussen V, Waumans Y, Martinet W, et al. Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis. Basic Res Cardiol 2013; 108: 350.
54. Waumans Y, Vliegen G, Maes L, et al. The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice. Inflammation 2016; 39: 413-24.
55. Zhang H, Chen Y, Wadham C, et al. Dipeptidyl peptidase 9 subcellular localization and a role in cell adhesion involving focal adhesion kinase and paxillin. Biochim Biophys Acta 2015; 1853: 470-80.
56. Yao TW, Kim WS, Yu DM, et al. A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling. Mol Cancer Res. 2011; 9: 948-59.
57. Pilla E, Möller U, Sauer G, et al. A novel SUMO1-specific interacting motif in Dipeptidyl peptidase 9 (DPP9) that is important for enzymatic regulation. J Biol Chem 2012; 287: 44320-9.
58. Justa-Schuch D, Silva-Garcia M, Pilla E, et al. DPP9 is a novel component of the N-end rule pathway targeting the tyrosine kinase Syk. Elife 2016; 5. pii: e16370.
59. Yu DM, Ajami K, Gall MG, et al. The In Vivo Expression of Dipeptidyl Peptidases 8 and 9. J Histochem Cytochem 2009; 57: 1025-40.
60. Harstad EB, Rosenblum JS, Gorrell MD, et al. DPP8 and DPP9 expression in cynomolgus monkey and Sprague Dawley rat tissues. Regul Pept 2013; 186: 26-35.
61. Dubois V, Lambeir AM, Van der Veken P, et al. Purification and characterization of dipeptidyl peptidase IV-like enzymes from bovine testes. Front Biosci 2008; 13: 3558-68.
62. Rettig WJ, Chesa PG, Beresford HR, et al. Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets. Cancer Res 1986; 46: 6406-12.
63. Lee KN, Jackson KW, Christiansen VJ, et al. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 2006; 107: 1397-404.
64. Edosada CY, Quan C, Tran T, et al. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett 2006; 580: 1581-6.
65. Aggarwal S, Brennen WN, Kole TP, et al. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry 2008; 47: 1076-86.
66. Lee KN, Jackson KW, Christiansen VJ, et al. A novel plasma proteinase potentiates a2-antiplasmin inhibition of fibrin digestion. Blood 2004; 103: 3783-8.
67. Christiansen VJ, Jackson KW, Lee KN, et al. Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV. Arch Biochem Biophys 2007; 457: 177-86.
68. Keane FM, Nadvi NA, Yao TW, et al. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-a. FEBS J 2011; 278: 1316-32.
69. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A 1990; 87: 7235-9.
70. Bauer S, Jendro MC, Wadle A, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 2006; 8: R171.
71. Brokopp CE, Schoenauer R, Richards P, et al. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur Heart J 2011; 32: 2713-22.
72. Levy MT, McCaughan GW, Abbott CA, et al. Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology 1999; 29: 1768-78.
73. Niedermeyer J, Garin-Chesa P, Kriz M, et al. Expression of the fibroblast activation protein during mouse embryo development. Int J Dev Biol 2001; 45: 445-7.
74. Keane FM, Yao TW, Seelk S, et al. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio 2013; 4: 43-54.
75. Roberts EW, Deonarine A, Jones JO, t al. Depletion of stromal cells expressing fibroblast activation protein-A from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med 2013; 210: 1137-51.
76. Dolznig H, Schweifer N, Puri C, et al. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun 2005; 5: 10.
77. Niedermeyer J, Kriz M, Hilberg F, et al. Targeted disruption of mouse fibroblast activation protein. Mol Cell Biol 2000; 20: 1089-94.
78. Rettig WJ, Garin-Chesa P, Beresford HR et al. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci U S A 1988; 85: 3110-4.
79. Ariga N, Sato E, Ohuchi N, et al Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer 2001; 95: 67-72.
80. Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 2012; 11: 257-66.
81. Tran E, Chinnasamy D, Yu Z, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med 2013; 210: 1125-35.
82. Wang LC, Lo A, Scholler J, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2014; 2: 154-66.
83. Santos AM, Jung J, Aziz N, et al. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 2009; 119: 3613-25.
84. Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010; 330: 827-30.
85. Walter R, Shlank H, Glass JD, et al. Leucylglycinamide released from oxytocin by human uterine enzyme. Science 1971; 173: 827-9.
86. Kato T, Okada M, Nagatsu T. Distribution of post-proline cleaving enzyme in human brain and the peripheral tissues. Mol Cell Biochem 1980; 32: 117-21.
87. Myöhänen TT, Pyykkö E, Männistö PT, et al. Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors. J Histochem Cytochem 2012; 60: 706-15.
88. Goossens F, De Meester I, Vanhoof G, et al. Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids. Eur J Clin Chem Clin Biochem 1996; 34: 17-22.
89. Overbeek SA, Braber S, Koelink PJ, et al. Cigarette smoke-induced collagen destruction; key to chronic neutrophilic airway inflammation? PLoS One 2013; 8: e55612.
90. Schulz I, Zeitschel U, Rudolph T, et al. Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J Neurochem 2005; 94: 970-9.
91. García-Horsman JA, Männistö PT, Venäläinen JI. On the role of prolyl oligopeptidase in health and disease. Neuropeptides 2007; 41: 1-24.
92. Brandt I, Scharpé S, Lambeir AM. Suggested functions for prolyl oligopeptidase: a puzzling paradox. Clin Chim Acta 2007; 377: 50-61.
93. Gaggar A, Jackson PL, Noerager BD, et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 2008; 180: 5662-9.
94. Weathington NM, van Houwelingen AH, Noerager BD, et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 2006; 12: 317-23.
95. Gaggar A, Weathington N. Bioactive extracellular matrix fragments in lung health and disease. J Clin Invest 2016; 126: 3176-84.
96. O'Reilly PJ, Hardison MT, Jackson PL, et al. Neutrophils contain prolyl endopeptidase and generate the chemotactic peptide, PGP, from collagen. J Neuroimmunol 2009; 217: 51-4.
97. Cavasin MA, Rhaleb NE, Yang XP, et al. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension. 2004; 43: 1140-5.
98. Brandt I, Gérard M, Sergeant K, et al. Prolyl oligopeptidase stimulates the aggregation of A-synuclein. Peptides 2008; 29: 1472-8.
99. Savolainen MH, Yan X, Myöhänen TT, et al. Prolyl oligopeptidase enhances a-synuclein dimerization via direct protein-protein interaction. J Biol Chem 2015; 290: 5117-26.
100. Matsuda T, Sakaguchi M, Tanaka S, et al. Prolyl oligopeptidase is a glyceraldehyde-3-phosphate dehydrogenase-binding protein that regulates genotoxic stress-induced cell death. Int J Biochem Cell Biol 2013; 45: 850-7.
101. Di Daniel E, Glover CP, Grot E, et al. Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity. Mol Cell Neurosci 2009; 41: 373-82.
102. Szeltner Z, Morawski M, Juhász T, et al. GAP43 shows partial co-localisation but no strong physical interaction with prolyl oligopeptidase. Biochim Biophys Acta 2010; 1804: 2162-76.
103. Myöhanen TT, Venalainen JI, Garcia-Horsman JA, et al. Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. J Comp Neurol 2008; 507: 1694-708.
104. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495: 251-4.
105. Meyerholz DK, Lambertz AM, McCray PB. Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome. Am J Pathol 2016; 186: 78-86.
106. van der Velden VH, Wierenga-Wolf AF, Adriaansen-Soeting PW, et al. Expression of aminopeptidase N and dipeptidyl peptidase IV in the healthy and asthmatic bronchus. Clin Exp Allergy 1998; 28: 110-20.
107. Landis BN, Grouzmann E, Monod M, et al. Implication of Dipeptidylpeptidase IV Activity in Human Bronchial Inflammation and in Bronchoconstriction Evaluated in Anesthetized Rabbits. Respiration 2008; 75: 89-97.
108. Grouzmann E, Monod M, Landis B, et al. Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa. FASEB J 2002; 16: 1132-4.
109. Juillerat-Jeanneret L, Aubert JD, Leuenberger P. Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: dipeptidyl (amino) peptidase IV, aminopeptidase N, and dipeptidyl (carboxy) peptidase (angiotensin-converting enzyme). J Lab Clin Med 1997; 130: 603-14.
110. Schade J, Stephan M, Schmiedl A, et al. Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats. J Histochem Cytochem 2008; 56: 147-55.
111. Baginski L, Tachon G, Falson F, et al. Reverse transcription polymerase chain reaction (RT-PCR) analysis of proteolytic enzymes in cultures of human respiratory epithelial cells. J Aerosol Med Pulm Drug Deliv 2011; 24: 89-101.
112. Nieto-Fontarigo JJ, González-Barcala FJ, San José E, et al. CD26 and Asthma: a Comprehensive Review. Clin Rev Allergy Immunol 2016. [Epub ahead of print].
113. Allen M, Heinzmann A, Noguchi E, et al. Positional cloning of a novel gene influencing asthma from chromosome 2q14. Nat Genet 2003; 35: 258-63.
114. Skripuletz T, Schmiedl A, Schade J, et al. Dose-dependent recruitment of CD25+ and CD26+ T cells in a novel F344 rat model of asthma. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1564-71.
115. Van Der Velden VH, Naber BA, et al. Peptidase activities in serum and bronchoalveolar lavage fluid from allergic asthmatics--comparison with healthy non-smokers and smokers and effects of inhaled glucocorticoids. Clin Exp Allergy 1999; 29: 813-23.
116. Shiobara T, Chibana K, Watanabe T, et al. Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells. Respir Res 2016; 17: 28.
117. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013; 45: 613-20.
118. Acharya PS, Zukas A, Chandan V, et al. Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol 2006; 37: 352-60.
119. Fan MH, Zhu Q, Li HH, et al. Fibroblast Activation Protein (FAP) Accelerates Collagen Degradation and Clearance from Lungs in Mice. J Biol Chem 2016; 291: 8070-89.
120. Braber S, Koelink PJ, Henricks PA, et al. Cigarette smoke-induced lung emphysema in mice is associated with prolyl endopeptidase, an enzyme involved in collagen breakdown. Am J Physiol Lung Cell Mol Physiol 2011; 300: L255-65.
121. Szul T, Bratcher PE, Fraser KB, et al. Toll-like receptor 4 engagement mediates prolyl endopeptidase release from airway epithelia via exosomes. Am J Respir Cell Mol Biol 2016; 54: 359-69.
122. National Cancer Institute. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer. Available online: http://seer. cancer. gov/statfacts/html/lungb. html
123. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83: 584-94.
124. Asada Y, Aratake Y, Kotani T, et al. Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma. Histopathology 1993; 23: 265-70.
125. Wesley UV, Tiwari S, Houghton AN. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer 2004; 109: 855-66.
126. Šedo A, Krepela E, Kasafírek E. Dipeptidyl peptidase IV prolyl endopeptidase and cathepsin B activities in primary human lung tumours and lung parenchyma. J Cancer Res Clin Oncol 1991; 117: 249-53.
127. Ivanov I, Tasheva D, Todorova R, et al. Synthesis and use of 4-peptidylhydrazido-N-hexyl-1, 8-naphthalimides as fluorogenic histochemical substrates for dipeptidyl peptidase IV and tripeptidyl peptidase I. Eur J Med Chem 2009; 44: 384-92.
128. Dimitrova M, Ivanov I, Todorova R, et al. Comparison of the activity levels and localization of dipeptidyl peptidase IV in normal and tumor human lung cells. Tissue Cell 2012; 44: 74-9.
129. Demuth HU, Baumgrass R, Schaper C, et al. Dipeptidylpeptidase IV--inactivation with N-peptidyl-O-aroyl hydroxylamines. J Enzyme Inhib 1988; 2: 129-42.
130. De Meester I, Vanhoof G, Hendriks D, et al. Characterization of dipeptidyl peptidase IV (CD26) from human lymphocytes. Clin Chim Acta 1992; 210: 23-34.
131. Křepela E, Vičcar J, Žižková L, et al. Dipeptidyl peptidase IV in mammalian lungs. Lung 1985; 163: 33-54.
132. Liao Y, Ni Y, He R, et al. Clinical implications of fibroblast activation protein-A in non-small cell lung cancer after curative resection: a new predictor for prognosis. J Cancer Res Clin Oncol 2013; 139: 1523-8.
133. Eager RM, Cunningham CC, Senzer N, et al. Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) 2009; 21: 464-72.
134. Inamoto T, Yamada T, Ohnuma K, et al. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res 2007; 13: 4191-200.
135. Fujimoto N, Ohnuma K, Aoe K, et al. Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma. Altomare DA, editor. PLoS One 2014; 9: e115647.
136. Liu PJ, Chen CD, Wang CL, et al. In-depth proteomic analysis of six types of exudative pleural effusions for nonsmall cell lung cancer biomarker discovery. Mol Cell Proteomics 2015; 14: 917-32.
137. Küpeli E, Karnak D, Elgün S, et al. Concurrent measurement of adenosine deaminase and dipeptidyl peptidase IV activity in the diagnosis of tuberculous pleural effusion. Diagn Microbiol Infect Dis 2009; 65: 365-71.
138. Wang H, Yue J, Yang J, et al. Clinical diagnostic utility of adenosine deaminase, interferon-γ, interferon-γ-induced protein of 10 kDa, and dipeptidyl peptidase 4 levels in tuberculous pleural effusions. Heart Lung 2012; 41: 70-5.
139. Orlowski M, Orlowski J, Lesser M, et al. Proteolytic enzymes in bronchopulmonary lavage fluids: cathepsin B-like activity and prolyl endopeptidase. J Lab Clin Med 1981; 97: 467-76.
140. Hardison MT, Galin FS, Calderon CE, et al. The presence of a matrix-derived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation. J Immunol 2009; 182: 4423-31.
141. Matheeussen V, Jungraithmayr W, De Meester I. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/ reperfusion injury. Pharmacol Ther 2012; 136: 267-82.
142. Hulver M, Lee JS, Fan M. Fibroblast Activation Protein (fap) Modulates Host Defense Against Bacterial Pneumonia In Mice. Am J Respir Crit Care Med 2015; 191: A6408.
143. Faillie JL, Filion KB, Patenaude V, et al. Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes. Diabetes Obes Metab 2015; 17: 379-85.
144. van der Zanden RW, de Vries F, Lalmohamed A, et al. Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study. PLoS One 2015; 10: e0139367.